title: [Sildenafil--for treatment of preeclampsia and intrauterine growth restriction].
abstract: Pre-eclampsia and intrauterine growth restriction (IUGR) are responsible for approximately 15-20% of serious maternal and neonatal diseases. These complications are related to very early anomalies of the uteroplacental circulation, accompanied, at least secondarily, by thromboxane-prostacyclin-related imbalances. Studies have failed to show a beneficial effect of betamimetics and calcium channel blockers for the treatment of IUGR. Sildenafil citrate, a type 5-specific phosphodiesterase inhibitor, augments the vasodilatory effects of NO by preventing the degradation of cGMP There is a selective effect of Sildenafil on the uteroplacental circulation. Sildenafil improves uterine artery blood flow.
authors.forename: M
authors.initials: M
authors.lastname: Malinova
mesh_terms: D005260:Female; D005317:Fetal Growth Retardation / Q000188:drug therapy*; D006801:Humans; D058986:Phosphodiesterase 5 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D011687:Purines / Q000494:pharmacology / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000494:pharmacology / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate